Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis plus Visudyne for subfoveal choroidal neovascularization due to age-related macular degeneration
2006-003976-36Phase 3Completed
- Sponsor
- UZ Leuven - Campus Sint-Rafaël
- Start
- Aug 2006
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab and verteporfin in age-related macular degeneration (AMD) and Subretinal neovascularization, sponsored by UZ Leuven - Campus Sint-Rafaël. Primary endpoint: Safety of combined therapy. Started Aug 2006; status: completed.
02
Drugs
ranibizumabverteporfin
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2006-003976-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003976-36.